Case Study: Second Genome achieves secure, scalable microbiome research with Provectus

Second Genome enhances its data platform to accelerate and scale biomarker research, drug trials and development in a secure and compliant environment

Second Genome, a biotechnology company focused on microbiome-based drug discovery and precision medicine, needed to accelerate and scale its research platform while improving data ingestion, staging, and codebase quality. Operating in a highly regulated pharmaceutical environment, the company also needed stronger data security and compliance to support work with industry, academia, government, and strategic partners such as Gilead Sciences. Provectus helped by improving the company’s data platform and preparing it for secure, scalable growth.

Provectus designed and built a secure, cloud-native data infrastructure on AWS, with automated CI/CD, centralized logging, disaster recovery, and security controls aligned to AWS healthcare data guidelines. The team also secured data in transit and at rest, eliminated open security groups, and supported anonymization and platform optimization work. As a result, Second Genome can now run petabyte-scale biomarker research, drug trials, and drug development projects in a compliant environment, speeding collaboration and making it easier to onboard premium biopharma partners.

Second Genome